Human 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) catalyzes the biosynthesis of the most potent natural estrogen 17β-estradiol (E2) from estrone (E1) in the ovary and peripheral tissues, playing a pivotal role in the progression of estrogen-dependent diseases. N-n-Butyl-N-methyl-ll-(16'α-chloro-3',17'β-dihydroxyestra-1',3',5'(10')-trien-7'α-yl)undecanamide (EM-139) was previously described as a dual-site inhibitor that can inhibit 17β-HSD1 transforming E1 into E2 and also inhibit estrogen receptor. In the present report, we describe the co-crystallization of EM-139 with 17β-HSD1 as well as the analysis of the three-dimensional structure of the enzyme/inhibitor complex. The crystal is grown under similar condition as native crystals, whereas the space group is changed to I121 never observed in other 17β-HSD1 crystals before. The steroidal moiety of the bound EM-139 molecule has shown a binding pattern similar to E2 in the E2 binary complex. The O-3 of the inhibitor develops hydrogen bonds with residues His 221 and Glu
Introduction
Seventeen β-hydroxysteroid dehydrogenase type 1 (17β-HSD1, EC. 1.1.1.62) catalyzes the NAD(P)H dependent conversion of estrone (E1) to the most potent estrogen, 17β-estradiol (E2) [1] . E2 is well known to play a crucial role in the progression and development of several estrogen-dependent diseases (EDD).
Increased E2 levels as well as up-regulated 17β-HSD1 expression indicate the involvement of the enzyme in EDDs, such as breast cancer [2] [3], endometrial cancer [4] [5], endometriosis [6] [7] [8] , and ovarian cancer [9] . Moreover, patients with tumors that have high mRNA levels of 17β-HSD1 have significantly shortened disease-free and overall survival [10] [11] [12] . Therefore, blocking the production of E2 through the specific inhibition of 17β-HSD1 activity is considered to be of therapeutic benefit in the treatment of EDDs.
Over the past decades, major efforts from many different laboratories have been devoted to developing highly selective inhibitors of the key steroidogenic enzyme 17β-HSD1, yielding several lead compounds with significant inhibitory activity [13] [14] . However, due to the lack of specificity, especially for the presence of undesired estrogenic activity, no inhibitor has yet reached the stage of clinical trials [15] [16] [17] [18] . N-n-Butyl-N-methyl-ll-(16'α-chloro-3',17'β-dihydroxyes-tra-1',3',5'(10')-trien-7'α-yl) undecanamide (EM-139) is a 7α-alkyl, 16α-halo estradiol derivative which was first synthesized as a pure antiestrogen ( Figure 1 ) [19] . Following experiments demonstrated its inhibitory effect on 17β-HSD1 activity with a K i of 6 μM [20] . Thus the compound was defined as a dual-site inhibitor which possesses inhibitory effect on estrogen receptor and on the estrogen formation [21] . Although this compound was proven to be a non-selective inhibitor of the 17β-HSD family members [22] , study of the EM-139/17β-HSD1 complex structure should help us to better understand the inhibitory mechanism of the dual-site inhibitor, thus facilitating further inhibitor design of the enzyme.
Previously, we have reported the crystallization of the 17β-HSD1/EM-139 complex using both co-crystallization and soaking methods [23] . The crystals obtained were isomorphous to the native crystals with a monoclinic space group C2 [23] . After careful analysis of the structures, the inhibitor couldn't be identified at the binding site of the enzyme due to poor electron density. In the present study, we optimized the co-crystallization procedure and successfully obtained complex crystals with a unique space group never observed in 17β-HSD1 complexes before. The clear electron density at the binding site indicated the presence of the dual-site inhibitor in the enzyme complex.
Materials and Methods

Protein Preparation and Co-Crystallization
The 17β-HSD1 enzyme was expressed in Sf9 insect cells and purified as described previously [24] . After the measurement of specific activity [25] , the purified enzyme was concentrated to a final concentration of 15 mg/ml in the pres-
ence of 0.06% β-octyl glucoside (β-OG), and then subjected to a buffer change procedure [26] via centricon (Emdmillipore, USA) to saturate the enzyme with the inhibitor EM-139. The co-crystallization experiment was carried out using the vapor diffusion method at room temperature. Crystals were obtained under conditions containing 22% -26% (w/v) polyethyleneglycol (PEG) 4000, 0.15 M magnesium chloride, and 0.1 M HEPES buffered to pH 7.5.
Data Collection and Structure Determination
The X-ray diffraction data of the 17β-HSD1-EM-139 crystals were collected at 100 K using synchrotron radiation at Advanced Photon Source (APS) beamline 31-LRL-CAT (Chicago, USA) equipped with a MAR CCD 165 mm detector at a wavelength of 0.9793 Å. The dataset was indexed and intergraded using MOSFLM [27] , and scaled with SCALA [28] from the CCP4 suite [29] . The structure was solved by molecular replacement with Molrep [30] using a reported 17β-HSD1 coordinate (PDB code 1JTV) [31] as search model. The initial model was subjected to multiple rounds of auto-refinement using Refmac [32] and manual rebuild using Coot [33] . Missing portions of the models, inhibitor EM-139, glycerol, polyethylene glycol, and water molecules were progressively added with great caution during the refinement procedure. The final model was verified with PROCHECK [34] . Molecular graphics were presented using the Pymol software (version 2.0 Schrödinger, LLC).
Results
Crystal utilized in this study belonged to space group I121 and each asymmetric unit contained a dimer, which is known to be the functional unit of the enzyme [25] . The complex structure was refined at 2 Å with good stereochemistries [35] , and the quality of the final model can be assessed in Table 1 [39].
In the binary complex structure, EM-139 has definable electron density in the A subunit of the dimeric enzyme. However, the ligand density in the B subunit is poorly defined, similar to previously described complex with equilin [40] . Accordingly the ligand was not included in the B subunit of the final model. Even for the A subunit, only the steroid moiety of EM-139 can be defined but with a high average B-factor (97.5 Å 2 ), whereas the 7α-alkyl side chain of the inhibitor cannot be defined in the electron density ( Figure 3 ). This high flexibility of the inhibitor is in accordance with its relatively low affinity for the enzyme [20] .
Discussion
The space group of 17β-HSD1 crystals can be affected by the presence of cations in the crystallization conditions [41] . The space group of crystals obtained in the are established, although the bond distances differ from their counterparts observed in the E2 complex (3.1 and 3.5 Å, respectively) [37] . Moreover, the bifurcated hydrogen bond between the 3-hydroxyl group of EM-139 with HisHealth 
Conclusion
The present work was aimed at investigating the molecular basis of the inhibitory mechanism of the dual-site inhibitor EM-139 in 17β-HSD1. We successfully hibitor molecule. However, the introduction of a bulky side chain at the C-7 of the steroid core, which contributes to the anti-estrogenic activity of the dual-site inhibitor, may negatively affect the binding of inhibitor to 17β-HSD1. These results will contribute to the design of more potent and selective inhibitors of 17β-HSD1 for clinical purposes.
